MedTrace Logo

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

NCT07680244 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-08-28

No results posted yet for this study

Summary

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

Conditions

  • Epiretinal Membrane
  • Dry Age Related Macular Degeneration
  • Macular Abnormalities
  • Retina Disease
  • Vitreoretinal Abnormality
  • Intraretinal Hyporeflective Space
  • Subretinal Hyporeflective Space
  • IS/OS (Ellipsoid Zone) Disruption
  • Retinal Pigment Epithelium (RPE) Elevation
  • Retinal Pigment Epithelium (RPE) Atrophy

Interventions

DEVICE

PathFinder 1.0 on CIRRUS HD-OCT

Participants undergo standard OCT imaging on CIRRUS HD-OCT systems, and the investigational PathFinder software analyzes the images for macular abnormalities without influencing clinical care.

Sponsors & Collaborators

  • Carl Zeiss Meditec-Dublin CoCe

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-23
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680244 on ClinicalTrials.gov